多西他赛联合顺铂治疗晚期非小细胞肺癌疗效观察

目的：观察多西他赛联合顺铂治疗非小细胞肺癌的临床疗效及不良反应。方法：对62例非小细胞肺癌患者采用多西他赛联合顺铂方案化疗，多西他赛75mg／m^2静脉滴注，d1；顺铂25mg／m^2静脉滴注d1-3；3周为一周期，至少治疗2周期。结果：所有患者均完成2个以上周期，有效率46．78％，中位生存期9．6个月。主要不良反应为脱发及骨髓抑制，发生率分别为88．71％及85．48％，其中Ⅲ-Ⅳ度分别为14．52％及8．06％。结论：多西他赛联合顺铂治疗非小细胞肺癌疗效显著，不良反应较小，患者耐受性好。

Clinical efficacy of combined chemotherapy with docetaxel and low -dose cisplatin for advanced non- small- cell lung cancer

Objective： To evaluate the therapeutic efficacy and toxicity of docetaxel combined with low - dose cis- platin as alternative chemotherapy for advanced non - small - cell lung cancer. Methods： Sixty - two patients with non - small - cell lung cancer received docetaxel combined with cisplatin chemotherapy, docetaxe175mg/m^2 infusion once per week for three weeks ,cisplatin 25mg/m^2 infusion on d1-3 for three weeks, after two consecutive therapy course, each for 3 weeks, evaluation of short term efficacy and side effects were carried out. Results ： All patients received more than 2 courses chemotherapy and the overall response rate was 46.78%, the median survival rate was 9.6 months. The main toxic reactions included alopecia and myelosuppression, the rates were 88.71% and 85.48%, grade Ⅲ- Ⅳreactive rates were 14.52% and 8.06%. Conclusion： Combined chemotherapy of docetaxel and low dose cisplatin for non - small - cell lung cancer is effective and well tolerated.